EnteroBiotix's EBX-102-02 Shows Promise as First-in-Class Oral Microbiome Therapy for Irritable Bowel Syndrome
核心洞察
EnteroBiotix (搜索) announced positive Phase 2a TrIuMPH trial results for EBX-102-02, demonstrating clinically meaningful improvements in IBS symptom severity as early as Week 1 and sustained through Week 7.
The oral full-spectrum microbiome therapeutic showed efficacy across both IBS-C (搜索) and IBS-D (搜索) subtypes, with 59% of patients achieving response versus 44% on placebo using a 50-point IBS-SSS reduction threshold.
EBX-102-02 was well tolerated with no serious drug-related adverse events, and the company plans to initiate a Phase 2b study in 2026 following FDA regulatory advice.
EnteroBiotix (搜索) Limited announced positive final results from its Phase 2a TrIuMPH clinical trial, demonstrating that EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, delivered clinically meaningful improvements in patients with irritable bowel syndrome (搜索) with constipation (IBS-C (搜索)) or diarrhea (IBS-D (搜索)). The 122-patient UK study showed clear separation from placebo as early as week 1, with benefits sustained throughout the six-week follow-up period.
Study Design and Patient Population
The TrIuMPH study was a UK-based, multicentre, randomised, double-blind, placebo-controlled Phase 2a trial enrolling 122 adults with moderate-to-severe IBS, including 62 patients with IBS-C (搜索) and 60 with IBS-D (搜索). Participants were randomised 2:1 to receive EBX-102-02 (8 capsules on Day 1 and Day 7) or matched placebo and were followed for six weeks after the first dose.
The study, registered as ISRCTN65517362 ("Treating IBS with an Intestinal Microbiota Product for Health"), was delivered with support from the Functional Gut Clinic (搜索) and included safety and tolerability as the primary endpoint, along with IBS symptom severity score (IBS-SSS), bowel habit diaries, validated patient-reported outcome measures, and changes in gut microbiome (搜索) structure and function.
Efficacy Results Across IBS Subtypes
EBX-102-02 demonstrated clinically meaningful improvements (≥50-point reduction) in the IBS symptom severity score in both IBS-C (搜索) and IBS-D (搜索) populations. The therapeutic effect was observed across multiple symptom domains, including abdominal pain, bowel habit parameters, and IBS-specific quality of life, with greater reductions versus placebo at all measured timepoints.
In post-hoc responder analysis using a ≥50-point IBS-SSS reduction threshold, 59% of patients treated with EBX-102-02 were responders at Week 7 compared with 44% on placebo across the overall IBS population. Using a more stringent ≥75-point reduction threshold, responder rates were 51% versus 33%, respectively.
Safety Profile and Tolerability
The primary endpoint of safety was met, with EBX-102-02 being generally well tolerated. Adverse events were primarily mild-to-moderate, self-limiting and gastrointestinal in nature. No severe or serious drug-related adverse events were reported, and no safety signals of concern were identified in either cohort. The safety profile was consistent with that observed in the company's IMPuLCE Phase 1b study in liver cirrhosis (搜索).
Microbiome Restoration Evidence
Preliminary shotgun metagenomic sequencing demonstrated that EBX-102-02 induced a broad and sustained shift in the gut microbiome (搜索) towards the composition of the administered product. These changes were observed in both IBS-C (搜索) and IBS-D (搜索) populations and were maintained through follow-up, providing evidence of microbiome ecosystem restoration.
Clinical Significance and Next Steps
Dr. James McIlroy, CEO of EnteroBiotix (搜索), stated: "The final TrIuMPH data demonstrate that EBX-102-02 has the potential to be a first-in-class, orally delivered, full-spectrum microbiome therapeutic for IBS, delivering clinically meaningful and durable improvements across multiple symptom domains in both IBS-C (搜索) and IBS-D (搜索)."
Mr. Paul Goldsmith MD, FRCS, Consultant General Surgeon at the University of Manchester NHS Trust (搜索) and Chief Investigator of the TrIuMPH study, noted: "IBS is a complex disease with a significant unmet medical need. The improvements in global symptom severity, abdominal pain, bowel habits and quality of life observed with EBX-102-02 in this study are clinically meaningful."
These results build on previously reported positive topline data from the IBS-C (搜索) cohort presented at Digestive Disease Week in San Diego in March 2025. EnteroBiotix (搜索) plans to submit the full TrIuMPH dataset for peer-reviewed scientific publication and to initiate an IBS-C Phase 2b study in 2026, aligned with recent FDA regulatory advice.
EBX-102-02 is manufactured using proprietary processing technologies that enable safe, stable and orally delivered microbial ecosystem restoration, designed to deliver consistently high microbial diversity with a robust stability profile.